CDSCO Panel Approves Novartis Protocol Amendment Proposal to study Ribociclib
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major Novartis' protocol amendment proposal for the clinical trial protocol titled, "A post-trial access roll-over study to allow access to ribociclib (LEE011) for patients who are on ribociclib treatment in Novartis-sponsored study.”
This came after Novartis presented protocol amendment version 01 dated 01 December 2023 protocol no. CLEE011A2412B.
LEE011 (ribociclib) is a selective cyclin dependent kinase inhibitor, a new class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin dependent kinase 4 and 6 (CDK4/6).
Ribociclib is a selective inhibitor of CDK4/6 that binds to the ATP-binding sites of these proteins. This blocks the CDK4/6-cyclin D-Rb-E2F axis, which reverses uncontrolled cell proliferation and tumor growth.
At the recent SEC meeting for Oncology held on 9th October 2024, the expert panel reviewed the protocol amendment version 01 dated 01 December 2023 protocol no. CLEE011A2412B
After detailed deliberation, the committee recommended the approval of the protocol amendment as presented by the firm.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.